{"disease":{"id":"advanced-or-metastatic-melanoma","name":"advanced or metastatic melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07280832","title":"Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":188,"lead_sponsor_name":"Shanghai JMT-Bio Inc.","has_results":false},{"nct_id":"NCT01783938","title":"Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":138,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03684785","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":57,"lead_sponsor_name":"Exicure, Inc.","has_results":false},{"nct_id":"NCT03673332","title":"Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"Institut Paoli-Calmettes","has_results":false},{"nct_id":"NCT05087602","title":"Toripalimab Combined With Anlotinib in Unresectable Locally Advanced or Metastatic Acral Malignant Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":29,"lead_sponsor_name":"Qilu Hospital of Shandong University","has_results":false},{"nct_id":"NCT04768881","title":"Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":15,"lead_sponsor_name":"Karyopharm Therapeutics Inc","has_results":true},{"nct_id":"NCT01864759","title":"Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":14,"lead_sponsor_name":"Institut Català d'Oncologia","has_results":false},{"nct_id":"NCT05498792","title":"Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Fox Chase Cancer Center","has_results":false}],"total":8},"guidelines":[],"source":"Drug Landscape verified database"}